John W. Hadden
Fondatore presso Virocell Biologics Ltd.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Farzin Farzaneh | M | - |
Virocell Biologics Ltd.
 Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | - |
| Kirk Calhoun | M | 80 | 8 anni | |
| Todd Davis | M | 63 |
Harvard Business School
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | 3 anni |
| Bob Casale | M | 65 | 8 anni | |
| J. Enloe | M | 60 |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | - |
| Srikant T. Madhav Datar | M | 70 |
Harvard Business School
| 28 anni |
| Thomas L. Long | M | - | 7 anni | |
| John Dawson | M | 64 |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | - |
| Peter Eric Priestley | M | 56 |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | - |
| Steven Valentino | M | - | 7 anni | |
| Joanne Cotignola | F | - | 5 anni | |
| Nick Maishman | M | - |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Bruce Robertson | M | 61 |
Harvard Business School
| 2 anni |
| Janet Barth | F | - | - | |
| Debi Kleiman | M | - |
Harvard Business School
| 2 anni |
| Scott Friend | M | 59 |
Harvard Business School
| 2 anni |
| Todd M. Abbrecht | M | 55 |
Harvard Business School
| 2 anni |
| Jun Yuan Feng | F | 55 |
Harvard Business School
| 2 anni |
| Francesca Fiore | F | 57 |
Harvard Business School
| 2 anni |
| Brent Johnstone | M | 53 |
Harvard Business School
| 2 anni |
| Juliette Rizkallah | F | 57 |
Harvard Business School
| 2 anni |
| Michael Cho | M | 55 |
Harvard Business School
| 2 anni |
| Harry James Wilson | M | 52 |
Harvard Business School
| 2 anni |
| Luke Sarsfield | M | 50 |
Harvard Business School
| 2 anni |
| Alex Behring da Costa | M | 57 |
Harvard Business School
| 2 anni |
| Tim Reed | M | 54 |
Harvard Business School
| 2 anni |
| Scott W. Rudmann | M | - |
Harvard Business School
| 2 anni |
| Lou Fouts | M | - |
Harvard Business School
| 2 anni |
| Nicholas Iacono | M | - |
Harvard Business School
| 2 anni |
| Dominic Ianno | M | 55 |
Harvard Business School
| 2 anni |
| Philip Thomas Blazek | M | 57 |
Harvard Business School
| 2 anni |
| Saquib Hussain Shirazi | M | - |
Harvard Business School
| 2 anni |
| Gideon Yu | M | 53 |
Harvard Business School
| 2 anni |
| Joe A. Del Guercio | M | 52 |
Harvard Business School
| 2 anni |
| Christian Lucas | M | 55 |
Harvard Business School
| 2 anni |
| Scott Fisher | M | - |
Harvard Business School
| 2 anni |
| Allison Mnookin | F | 53 |
Harvard Business School
| 2 anni |
| Craig Kennedy | M | - |
Harvard Business School
| 2 anni |
| Colleen Durham Craig | F | - |
Harvard Business School
| 2 anni |
| Dean Dorman | M | - |
Harvard Business School
| 2 anni |
| Wendy Phillips | F | - |
Harvard Business School
| 2 anni |
| Rick Marini | M | - |
Harvard Business School
| 2 anni |
| Bill Nussey | M | - |
Harvard Business School
| 2 anni |
| JB Lyon | M | - |
Harvard Business School
| 2 anni |
| Fitzgerald C.J. | M | - |
Harvard Business School
| 2 anni |
| Fersen Lamas Lambranho | M | - |
Harvard Business School
| 4 anni |
| Karen Gordon | F | - |
Harvard Business School
| 2 anni |
| Jeff M. Anapolsky | M | - |
Harvard Business School
| 4 anni |
| Charles Baillie | M | - |
Harvard Business School
| 2 anni |
| Buddy Gumina | M | - |
Harvard Business School
| 92 anni |
| Dyice Ellis Beckham | F | - |
Harvard Business School
| 2 anni |
| Johan Depraetere | M | 56 |
Harvard Business School
| 4 anni |
| Ravin Agrawal | M | - |
Harvard Business School
| 4 anni |
| Patrick Berkhouwer | M | 56 |
Harvard Business School
| 2 anni |
| John Bachman | M | 68 |
Harvard Business School
| 2 anni |
| Anjai Ghandi | M | - |
Harvard Business School
| 2 anni |
| Tope Lawani | M | 53 |
Harvard Business School
| 2 anni |
| Stephen Harris Golden | M | - |
Harvard Business School
| 2 anni |
| Richard L. Bauerly | M | - |
Harvard Business School
| 2 anni |
| Jeffrey Michael Jacobe | M | - |
Harvard Business School
| 2 anni |
| Roger George Kuo | M | - |
Harvard Business School
| 2 anni |
| Daphne Dufresne | F | 52 |
Harvard Business School
| 2 anni |
| Allen Moseley | M | 54 |
Harvard Business School
| 2 anni |
| Vinton Albert George Vickers | M | - |
Harvard Business School
| 2 anni |
| Will Beamer | M | 54 |
Harvard Business School
| 2 anni |
| Chris Wallis | M | - |
Harvard Business School
| 2 anni |
| Reynaldo Reza | M | - |
Harvard Business School
| 2 anni |
| David S. B. Lang | M | 57 |
Harvard Business School
| 2 anni |
| Venu Shamapant | M | 56 |
Harvard Business School
| 2 anni |
| Todd Foley | M | 52 |
Harvard Business School
| 2 anni |
| Jennifer Scott Fonstad | F | 58 |
Harvard Business School
| 1 anni |
| Evan Guillemin | M | 58 |
Harvard Business School
| 2 anni |
| Denise Warren | F | 62 |
Harvard Business School
| 2 anni |
| Marc Lipschultz | M | 54 |
Harvard Business School
| 2 anni |
| Kathleen Mitic | F | 54 |
Harvard Business School
| 2 anni |
| Catherine Szyman | F | 57 |
Harvard Business School
| - |
| Myra Maloney Hart | M | 82 |
Harvard Business School
| 13 anni |
| Bruce Jacobs | M | 54 |
Harvard Business School
| 2 anni |
| Andrew Peter Seamons | M | - |
Harvard Business School
| 2 anni |
| Eric Zinterhofer | M | 52 |
Harvard Business School
| 2 anni |
| Dale LeFebvre | M | 53 |
Harvard Business School
| 3 anni |
| Ted Seides | M | 54 |
Harvard Business School
| 2 anni |
| Jason S. Mozingo | M | - |
Harvard Business School
| 2 anni |
| Clark Crosnoe | M | 56 |
Harvard Business School
| 2 anni |
| Matthew Botein | M | 51 |
Harvard Business School
| 2 anni |
| Ajit Nedungadi | M | 54 |
Harvard Business School
| 2 anni |
| Jim Schwab | M | - |
Harvard Business School
| 2 anni |
| Edward Herring | M | 53 |
Harvard Business School
| 2 anni |
| Raul R. Rai | M | - |
Harvard Business School
| 2 anni |
| Mark Fernandes | M | - |
Harvard Business School
| 2 anni |
| Timothy Connors | M | 57 |
Harvard Business School
| 2 anni |
| Benjamin Sebel | M | - |
Harvard Business School
| 2 anni |
| Soren L. Oberg | M | 47 |
Harvard Business School
| 2 anni |
| Kenneth Bailey | M | 55 |
Harvard Business School
| 2 anni |
| Randi Cosentino | M | 50 |
Harvard Business School
| 2 anni |
| Jeffrey Housenbold | M | 54 |
Harvard Business School
| 2 anni |
| John McDonough | M | 60 |
Harvard Business School
| 2 anni |
| Anders Richardson | M | - |
Harvard Business School
| 2 anni |
| Jed A. Smith | M | - |
Harvard Business School
| 2 anni |
| Josh Freeman | M | - |
Harvard Business School
| 3 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 95 | 95.00% |
| Regno Unito | 6 | 6.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- John W. Hadden
- Contatti personali
